Vividrin

Overdose

As sodium cromoglycate is absorbed only to a very limited extent from eye drops, no action other than medical observation should be necessary.

Shelf life

Unopened: 36 months.

Once opened for the first time: 1 month.

Vividrin price

We have no data on the cost of the drug.
However, we will provide data for each active ingredient

Contraindications

Known hypersensitivity to benzalkonium chloride, sodium cromoglycate or other constituents.

Incompatibilities

Sodium cromoglycate forms insoluble complexes with metal ions resulting in solution turbidity.

List of excipients

Benzalkonium chloride EP

Edetic acid disodium salt 2H2O EP

Polysorbate 80 EP

Sorbitol EP

Sodium hydroxide EP

Purified water EP

Pharmaceutical form

Sterile Preserved Multidose Eye Drops.

Undesirable effects

Transient stinging and burning may occur after instillation, other symptoms of local irritation have been reported rarely.

Preclinical safety data

The results of the studies do not add to the information needed by the prescriber, consequently, they are not repeated in the SPC.

Therapeutic indications

Vividrin Eye Drops are for the prophylaxis and symptomatic treatment of acute allergic conjunctivitis, chronic allergic conjunctivitis and vernal kerato conjunctivitis.

Vividrin Hay Fever Eye Drops are for the treatment of acute seasonal allergic conjunctivitis.

Pharmacodynamic properties

Sodium cromoglycate has neither anti-histaminic or anti-inflammatory activity. Evidence suggests that sodium cromoglycate inhibits the release of mediators of the allergic reaction by stabilising the membranes of sensitised mast cells.

Pharmacokinetic properties

Due to lipid insolubility, sodium cromoglycate is poorly absorbed following administration to the eye. In normal volunteers approximately 0.03% is systemically absorbed. Absorbed sodium cromoglycate is excreted unchanged in the bile and urine.

Trace amounts of sodium cromoglycate have been detected in the aqueous humor of rabbits for up to 24 hours after treatment.

Date of revision of the text

Not applicable

Marketing authorisation holder

Pharma Global Limited

Hudson Road

Sandycove

Co Dublin

Ireland

Special precautions for storage

Store below 25ºC, out of direct sunlight.

Nature and contents of container

Vividrin Eye Drops - 13.5ml polyethylene multidose eye dropper bottle with polyethylene cap.

Vividrin Hay Fever Eye Drops - 10.0ml polyethylene multidose eye dropper bottle with polyethylene cap.

Marketing authorisation number(s)

PL 11185/0004

Qualitative and quantitative composition

Active

Sodium cromoglycate EP 2.00% w/v.

Special warnings and precautions for use

The solution should be discarded 1 month after first opening the bottle or if any turbidity develops. Do not use if the bottle has been opened prior to receipt. Vividrin Eye Drops and Vividrin Hay Fever Eye Drops contain benzalkonium chloride. Do not wear soft contact lenses during the period of use.

Effects on ability to drive and use machines

Transient stinging or blurred vision may occur on instillation. Do not drive or operate machinery until proper vision is restored.

Dosage (Posology) and method of administration

Route of Administration:

For topical administration to the eye.

Adults, Children and the Elderly

One or two drops into each eye up to four times daily.

Special precautions for disposal and other handling

The following instructions for use are included in the patient leaflet.

1. Before using your Vividrin Eye Drops (Vividrin Hay Fever Eye Drops) you should wash your hands.

2. You may find it helps to sit in front of a mirror, so that you can see what you are doing. Gently pull down your lower eyelid and carefully place one or two Vividrin Eye Drops (Vividrin Hay Fever Eye Drops) in the space between the eyelid and the eye. Take care not to touch the dropper with your eye or fingers.

3. Release the eyelid and blink a few times to make sure the liquid covers the whole surface of the eye.

4. Repeat the procedure with the other eye and then replace the cap on the bottle.

Date of first authorisation/renewal of the authorisation

13th December 1996